株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

下垂体ACTH過剰分泌 (クッシング病) :パイプライン製品の分析

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 253635
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.16円で換算しております。
Back to Top
下垂体ACTH過剰分泌 (クッシング病) :パイプライン製品の分析 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016
出版日: 2016年12月21日 ページ情報: 英文 79 Pages
概要

クッシング病は、下垂体から副腎皮質刺激ホルモン (ACTH) が過剰に放出された状態を指します。にきび、皮膚感染症、腰痛、精神的変化、行動の変化、頭痛などの症状が見られます。治療には、外科手術と放射線療法が含まれます。

当レポートでは、下垂体ACTH過剰分泌 (クッシング病) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤プロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

下垂体ACTH過剰分泌 (クッシング病) の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Alder Biopharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Cortendo AB
  • Cyclacel Pharmaceuticals, Inc.
  • ElexoPharm GmbH
  • Ipsen S.A.
  • Isis Pharmaceuticals, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ALD-1613
  • AT-814
  • ATR-101
  • BIM-23A758
  • COR-005
  • CORT-125134
  • ISIS-GCCRRx
  • ketoconazole
  • mifepristone
  • MPP-482
  • osilodrostat
  • pasireotide LAR
  • Peptides to Antagonize ACTH Receptor for Cushing's Syndrome
  • seliciclib
  • Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease
  • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease
  • Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism
  • Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8826IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H2 2016, provides an overview of the Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline landscape.

Cushing disease is a condition in which the pituitary gland releases too much adrenocorticotropic hormone (ACTH). Symptoms include acne or skin infections, backache, mental changes, such as depression, anxiety, or changes in behavior. Treatment includes surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pituitary ACTH Hypersecretion (Cushing Disease) Overview
  • Therapeutics Development
  • Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
    • Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis
    • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Development by Companies
    • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Investigation by Universities/Institutes
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Development by Companies
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Investigation by Universities/Institutes
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
    • Amryt Pharma plc
    • Corcept Therapeutics Inc
    • Cyclacel Pharmaceuticals Inc
    • ElexoPharm GmbH
    • Ipsen SA
    • Millendo Therapeutics Inc
    • Novartis AG
    • Orphagen Pharmaceuticals Inc
    • Pfizer Inc
    • Reset Therapeutics Inc
    • Strongbridge Biopharma plc
    • XOMA Corp
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIM-23B065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levoketoconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mifepristone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPP-482 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • osilodrostat phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seliciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veldoreotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
      • Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
      • Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014
      • Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014
      • Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
      • Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
      • Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial
      • Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing's Syndrome
      • Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing's Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2016
  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Amryt Pharma plc, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Corcept Therapeutics Inc, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by ElexoPharm GmbH, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Ipsen SA, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Millendo Therapeutics Inc, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Novartis AG, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Pfizer Inc, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Reset Therapeutics Inc, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by XOMA Corp, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H2 2016
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2016
  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top